earnings
confidence high
sentiment positive
materiality 0.80
Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76
EXELIXIS, INC.
2024-FY EPS reported
$1.76
revenue$2,168,701,000
- Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.
- GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.
- Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.
- Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B.